Spark, Selecta in Gene-Therapy Deal Worth Up to $460 Million
By
Spark Therapeutics, a Philadelphia-based late clinical-stage gene therapy company, has entered into a license agreement with Selecta Biosciences, a Watertown, Massachusetts-based clinical-stage biopharmaceutical company, for the exclusive worldwide rights to…